Tendencias21

Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer ‘promising’

Addition of Bevacizumab to the existing standard of care was safe and showed promising overall results. The two- and three- year overall survival rates were 89.8 percent and 80.2 percent, respectively.

Fuente : http://www.eurekalert.org/pub_releases/2014-01/uoc…

RedacciónT21

RedacciónT21

Hacer un comentario